Table 3 MCL1, BCL2, BCL-XL gene expression in AML cases (n = 70)
| Â | MCL1 | BCL2 | BCL-XL | ||||||
|---|---|---|---|---|---|---|---|---|---|
Negative (n = 24) | Positive (n = 46) | P | Negative (n = 20) | Positive (n = 50) | P | Negative (n = 24) | Positive (n = 46) | P | |
FAB | |||||||||
 APL (n = 11)* | 5 | 6 | NS | 5 | 6 | NS | 5 | 6 | NS |
 Non-APL (n = 59) | 19 | 40 | 15 | 44 | 19 | 40 | |||
Performance status | |||||||||
0/1 (n = 33) | 14 | 19 | NS | 8 | 25 | NS | 16 | 17 | NS |
2/3 (n = 37) | 10 | 27 | 12 | 25 | 8 | 29 | |||
Early death†| |||||||||
 No (n = 48) | 17 | 31 | NS | 10 | 38 | 0.02 | 17 | 31 | NS |
 Yes (n = 20) | 7 | 13 | 10 | 10 | 7 | 13 | |||
Apoptosis medians (ranges) | |||||||||
 Annxine V | 3.8 (0.4–9.1) | 4.9 (0.3–13.6) | NS | 2.7 (0.4–8.4) | 4.8 (0.3–13.6) | 0.03 | 3.8 (0.4–9.5) | 4.5 (0.3–13.6) | NS |
 Anx&PI‡ | 3.4 (0.6–13.9) | 5.5 (0.6–17.1) | NS | 2.5 (0.6–7.8) | 5.5 (0.6–17.1) | 0.003 | 3.5 (0.6–12.3) | 5.5 (0.6–17.1) | NS |
 Total apoptosis | 8.3 (1.7–18.6) | 10.4 (2.9–19.3) | NS | 4.6 (1.7–14.3) | 11.1 (2.9–19.3) | 0.001 | 8.3 (1.7–17.7) | 10.4 (2.9–19.3) | NS |